Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 42, Issue 8 (Aug 2004)

Issues

Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity

Nikoleta Ziouti
  • Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
/ Demitrios H. Vynios
  • Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
/ Alexios J. Aletras
  • Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
/ Dora Kyriakopoulou
  • Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
/ Anna Mastorakou
  • Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
/ Andreas Andonopoulos
  • Rheumatology Clinic, University Hospital and Department of Medical Sciences, University of Patras, Patras, Greece
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.143

Abstract

Matrix metalloproteinases participate in the degradation of the extracellular matrix proteins and are regulated mainly by their respective tissue inhibitors. In a variety of inflammatory connective tissue diseases, variations in the tissue content of both metalloproteinases and tissue inhibitors have been reported. The purpose of this study was to determine the serum levels of metalloproteinases and tissue inhibitors in patients with autoimmune diseases and compare with those of healthy individuals of similar age. The metalloproteinase content was analyzed by zymography and it was found that the serum levels of metalloproteinase-2 and metalloproteinase-9 of all autoimmune disease samples were decreased, in all diseases examined and independently of clinical activity, while those of active metalloproteinase-9 were significantly elevated. Both tissue inhibitors were quantitated by direct enzyme-linked immunosorbent assay and were also found decreased in autoimmune disease samples, confirming the balance that should exist in the secretion of metalloproteinases and tissue inhibitors. These results suggested that the increased active form of metalloproteinase-9, together with the decreased concentration of tissue inhibitor-2, could be used for diagnostic purposes and for the follow-up of patients with autoimmune diseases.

Keywords: ageing; enzymes; osteoarthritis; rheumatoid arthritis

References

  • 1

    Gartaganis SP, Georgakopoulos CD, Mela EK, Exarchou A, Ziouti N, Assouti M, et al. Matrix metalloproteinases and their inhibitors in exfoliation syndrome. Opthalmic Res 2002; 34:165–71.

  • 2

    Preston A. Extracellular Matrix Proteases & Proteins Technical Guide. Calbiochem® and Oncogene™ Research Products, 2002.

  • 3

    Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127:393–8.

  • 4

    Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001; 125:340–4.

  • 5

    Syggelos SA, Eleftheriou SC, Giannopoulou E, Panagiotopoulos E, Aletras A. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. J Rheumatol 2001; 28:1319–29.

  • 6

    Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004; 10:1057–63. [Crossref]

  • 7

    Deutscher MP. One-dimensional gel electrophoresis. In: Deutscher MP, editor. Methods in enzymology. San Diego, CA: Academic Press, 1990;182:425pp.

  • 8

    Patron CF, Zouki C, Whittal RM, Chan JSD, Davidge ST, Filep JG. Methods for analysis of matrix metalloproteinase regulation of neutrophil-endothelial cell adhesion. Biol Proced Online 2002; 4:38–48.

  • 9

    Ziouti N, Triantaphyllidou IE, Assouti M, Papageorgakopoulou N, Kyriakopoulou D, Anagnostides ST, et al. Solid phase assays in extracellular glycoconjugate research. J Pharm Biomed Anal 2004; 34:771–89.

  • 10

    Murphy G, Koklitis P, Carne AF. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. Biochem J 1989; 261:1031–4.

  • 11

    Ribbens C. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002; 61:161–6.

  • 12

    Zucker S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999; 878:212–27.

  • 13

    Avolio C, Ruggieri M, Giulani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136:46–53.

  • 14

    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 2002; 41:78–87.

  • 15

    Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996; 78:161–71.

  • 16

    Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 6:473–88. [Crossref]

  • 17

    Yoshihara Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59:455–61.

  • 18

    Perez P. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 2000; 43:2807–17.

  • 19

    Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003; 70:373–8.

  • 20

    Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel A, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13:1550–7. [Crossref]

  • 21

    Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003; 49:339–40.

  • 22

    Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314:241–4.

  • 23

    Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 (MMP-9) in human plasma. Anal Biochem 2003; 322:283–6.

  • 24

    Makowskia GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003; 329:77–81.

  • 25

    Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002; 20:221–4.

About the article

Corresponding author: Demitrios H. Vynios, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece. Phone: +30-2610-997876, Fax: +30-2610-997154, E-mail:


Received: 2004-03-08

Accepted: 2004-05-10

Published Online: 2005-06-01

Published in Print: 2004-08-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.143. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
N. Ziouti, N.S. Mastronikolis, A.P. Andonopoulos, C.D. Georgakopoulos, and D.H. Vynios
Analytical Biochemistry, 2006, Volume 350, Number 1, Page 159
[3]
Chris C. Woods, Krishnan Sundar, Cynthia Tessler, Ty W. Lebsack, Lora Grainger, Alma Nielsen, David Bleich, and Dominick DeLuca
Journal of Autoimmunity, 2006, Volume 27, Number 1, Page 28

Comments (0)

Please log in or register to comment.
Log in